{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=nicotinamide&page=2",
    "query": {
      "intervention": "nicotinamide",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=nicotinamide&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-20T16:28:22.500Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00304993",
      "title": "Study of Niacin and Rosiglitazone in Dysmetabolic Dyslipidemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Metabolic Syndrome X",
        "Insulin Resistance"
      ],
      "interventions": [
        {
          "name": "fenofibrate",
          "type": "DRUG"
        },
        {
          "name": "niacin",
          "type": "DRUG"
        },
        {
          "name": "rosiglitazone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Foundation Research, Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2001-01",
      "completion_date": "2005-02",
      "has_results": false,
      "last_update_posted_date": "2006-03-21",
      "last_synced_at": "2026-09-20T16:28:22.500Z",
      "location_count": 1,
      "location_summary": "St. Petersburg, Florida",
      "locations": [
        {
          "city": "St. Petersburg",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00304993"
    },
    {
      "nct_id": "NCT01239004",
      "title": "Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Dyslipidemia",
        "Hyperlipidemia",
        "Hyperglycemia"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Colesevelam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Radiant Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 140,
      "start_date": "2010-11",
      "completion_date": "2011-08",
      "has_results": false,
      "last_update_posted_date": "2012-01-06",
      "last_synced_at": "2026-09-20T16:28:22.500Z",
      "location_count": 4,
      "location_summary": "Chicago, Illinois • Kansas City, Kansas • Minneapolis, Minnesota + 1 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01239004"
    },
    {
      "nct_id": "NCT02303444",
      "title": "An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Thyroid Neoplasms"
      ],
      "interventions": [
        {
          "name": "Sorafenib (Nexavar, BAY43-9006)",
          "type": "DRUG"
        },
        {
          "name": "Other Multikinase inhibitors",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 667,
      "start_date": "2015-04-08",
      "completion_date": "2020-07-24",
      "has_results": false,
      "last_update_posted_date": "2023-06-08",
      "last_synced_at": "2026-09-20T16:28:22.500Z",
      "location_count": 16,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Torrance, California + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02303444"
    },
    {
      "nct_id": "NCT02323906",
      "title": "Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoma, Hepatocellular"
      ],
      "interventions": [
        {
          "name": "CC-122",
          "type": "DRUG"
        },
        {
          "name": "Sorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2015-01-16",
      "completion_date": "2016-12-21",
      "has_results": false,
      "last_update_posted_date": "2017-03-20",
      "last_synced_at": "2026-09-20T16:28:22.500Z",
      "location_count": 8,
      "location_summary": "San Francisco, California • Gainesville, Florida • Tampa, Florida + 5 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02323906"
    },
    {
      "nct_id": "NCT00696696",
      "title": "Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Erlotinib",
          "type": "DRUG"
        },
        {
          "name": "Sorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2007-09",
      "completion_date": "2013-06",
      "has_results": true,
      "last_update_posted_date": "2016-06-30",
      "last_synced_at": "2026-09-20T16:28:22.500Z",
      "location_count": 3,
      "location_summary": "Palm Springs, California • New York, New York",
      "locations": [
        {
          "city": "Palm Springs",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00696696"
    },
    {
      "nct_id": "NCT00119249",
      "title": "Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage III Melanoma",
        "Stage IV Melanoma"
      ],
      "interventions": [
        {
          "name": "sorafenib tosylate",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 74,
      "start_date": "2005-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-15",
      "last_synced_at": "2026-09-20T16:28:22.500Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00119249"
    },
    {
      "nct_id": "NCT01887717",
      "title": "Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "TheraSphere®",
          "type": "DEVICE"
        },
        {
          "name": "Sorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Boston Scientific Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2014-02-27",
      "completion_date": "2017-05-23",
      "has_results": true,
      "last_update_posted_date": "2021-04-21",
      "last_synced_at": "2026-09-20T16:28:22.500Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • New York, New York",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01887717"
    },
    {
      "nct_id": "NCT00694291",
      "title": "Sorafenib in Hormone Naïve Biochemical Recurrence of Prostate Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Sorafenib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fox Chase Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 0,
      "start_date": "2008-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2015-03-06",
      "last_synced_at": "2026-09-20T16:28:22.500Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00694291"
    },
    {
      "nct_id": "NCT02000440",
      "title": "A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glomerulosclerosis, Focal Segmental"
      ],
      "interventions": [
        {
          "name": "Losmapimod",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 17,
      "start_date": "2014-07-01",
      "completion_date": "2016-05-11",
      "has_results": true,
      "last_update_posted_date": "2017-06-12",
      "last_synced_at": "2026-09-20T16:28:22.500Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Stanford, California • New Orleans, Louisiana + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02000440"
    },
    {
      "nct_id": "NCT00508885",
      "title": "The Effect of Oral Niacinamide on Plasma Phosphorus Levels in Peritoneal Dialysis Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hyperphosphatemia"
      ],
      "interventions": [
        {
          "name": "Niacinamide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2006-10",
      "completion_date": "2007-07",
      "has_results": false,
      "last_update_posted_date": "2007-07-30",
      "last_synced_at": "2026-09-20T16:28:22.500Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00508885"
    }
  ]
}